The purpose of this study is to evaluate the effect of mivelsiran on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics of mivelsiran in adults with sporadic CAA or Dutch-type CAA. See the sponsor’s trial website (https://clinicaltrials.alnylam.com/trials/6393712) for more information.